


# Amaxa™ 96-well Shuttle™ Protocol for Mature Mouse Dendritic Cells

# **Cell Description**

Progenitor cells derived from mouse bone marrow; non-adherent or loosely adherent cells of irregular shape with typical protrusions ("dendrites") of variable shape and length.

## **Example for Nucleofection™ of Mature Mouse Dendritic Cells**



Average transfection efficiency and viability of mature mouse dendritic cells 24 hours post Nucleofection\*\*.  $2.5 \times 10^4$  mature mouse dendritic cells were transfected with program 96-DN-107 and  $0.4 \mu g$  of pmaxGFP\*\*Vector. 24 hours post Nucleofection\*\* cells were analyzed on a FACSCalibur\*\* with HTS option (Becton Dickinson). Cell viability was approximately 85 % after 24 hours (compared to PI negative cells of untreated control).

# **Product Description**

## **Recommended Kits**

P3 Primary Cell 96-well Nucleofector™ Kits

Cat. No.	V4SP-3096
Size (reactions)	1×96
P3 Primary Cell 96-well Nucleofector™ Solution	2.25 ml
Supplement	0.5 ml
pmaxGFP™ Vector (1 μg/μl in 10 mM Tris pH 8.0)	50 μg
Nucleocuvette™ Plate(s)	1

Cat. No.	V4SP-3960
Size (reactions)	10×96
P3 Primary Cell 96-well Nucleofector™ Solution	22.5 ml
Supplement	5 ml
pmaxGFP™ Vector (1 μg/μl in 10 mM Tris pH 8.0)	50 μg
Nucleocuvette™ Plate(s)	10

# Storage and Stability

Store Nucleofector Solution, Supplement and pmaxGFP Vector at  $4^{\circ}$ C. For long-term storage, pmaxGFP Vector is ideally stored at  $-20^{\circ}$ C. The expiration date is printed on the solution box. Once the Nucleofector Supplement is added to the Nucleofector Solution, it is stable for three months at  $4^{\circ}$ C.

#### Note

96-well Nucleofector™ Solutions can only be used with conductive polymer cuvettes, i.e. in the 96-well Shuttle™ Device and in the 4D-Nucleofector™ System. They are not compatible with the Nucleofector™ II/2b Device

# Required Material

#### Note

Please make sure that the entire supplement is added to the Nucleofector™ Solution.

- Nucleofector™96-well Shuttle System (Nucleofector™ Device, version IIS;
   96-well Shuttle™ Device; laptop with 96-well Shuttle™ Software)
- Supplemented 96-well Nucleofector™ Solution at room temperature
- Supplied Nucleocuvette<sup>™</sup> Plate(s)
- Supplied pmaxGFP™ Vector, stock solution 1 μg/μl

#### Note

Volume of substrate solution added to each sample should not exceed 10 % of the total reaction volume (2  $\mu$ l for 20  $\mu$ l reactions). For positive control using pmaxGFP<sup>TM</sup> Vector, please dilute the stock solution to reach the appropriate working concentration.

 Substrate of interest, highly purified, preferably by using endotoxinfree kits; A260 : A280 ratio should be at least 1.8

#### Note

As contamination of the DNA with low molecular weight compounds may reduce cell viability, we strongly recommend performing an additional purification step after using a plasmid purification kit. Therefore precipitate the purified DNA twice using 20 % PEG/2.5 M NaCl (final concentration).

- Nucleocuvette™ compatible tips: epT.I.P.S. (US/CDN: Eppendorf North America, Cat. No. 2491.431, Rest of World: Eppendorf AG, Cat. No. 0030073.266), Matrix TallTips™ (Matrix Technologies Corp., Cat. No. 7281) or LTS Tips (Rainin Instrument, LLC, Cat. No. SR-L10F, SR/SS-L250S, SR/SS-L300S). Before using other types of pipette tips, please ensure they reach the bottom of the Nucleocuvette™ Wells without getting stuck
- 96-well culture plates or culture plates of your choice
- Culture medium I: RPMI 1640 (Lonza; Cat. No. 12-167F) supplemented with 10% calf serum (FCS), 100µg/ml streptomycin, 100U/ml Penicilin, 2 mM glutamine and 2000 U/ml GM-CSF (BD Pharmingen; Cat. No.: 554586)
- Culture medium II: Culture medium I without GM-CSF
- $-\,$  Maturation medium: Culture medium I with 0.1  $\mu g/mI$  LPS (Sigma, Cat. No. L-9764)
- Prewarm appropriate volume of culture medium to 37°C (190 μl per sample)
- Appropriate number of cells (2.5×10<sup>4</sup> cells per sample; lower or higher cell numbers may influence transfection results)

# 1. Pre Nucleofection™

# Preparation of Cells and Cell Culture

## **Preparation of Bones**

1.1 Carefully remove the femurs and tibia of freshly prepared mouse hind legs using forceps and scissors. Cut off both ends of the hones

#### Isolation of Dendritic Cells

- 1.2 Use a 27G needle mounted to a 5 ml syringe to gently flush the bone marrow into a petri dish. Use 2–3 ml culture medium II per bone
- 1.3 Count the viable cells
- 1.4 Spin down cells at 300×g for 10 minutes at RT and discard the supernatant
- 1.5 Resuspend the cell pellet in culture medium I to reach a cell density of  $1\times10^6$  cells/ml
- 1.6 Transfer the cells into 24-well plates (1 ml/well) and incubate them in a 37°C incubator with a 5 % CO<sub>2</sub> atmosphere

#### Note

To yield a high number of functional dendritic cells it is necessary to maintain a sufficient level of GM-CSF. Fresh Fresh culture medium I (containing GM-CSF) should be added every second day.

- 1.7 On day 2, carefully remove 700  $\mu$ l of the cell medium from each well and replace it by fresh culture medium I, to maintain an appropriate GM-CSF concentration
- 1.8 Remove and discard the cell medium completely on day 3. Wash the cells carefully with 500µl per well using culture medium II to remove residual non adherent cells and add 1 ml fresh culture medium I per well
- 1.8 Incubate the cells at  $37^{\circ}$ C in an incubator with 5% CO<sub>2</sub> atmosphere

## **Maturation of Dendritic Cells**

- 1.10 To generate mature dendritic cells stimulate the immature cells with 0.1  $\mu$ g/ml LPS. Therefore remove 1 ml of the cell supernatant on day 6 and replace it by 1 ml plating medium supplemented with 0.1  $\mu$ g LPS/ml
- 1.11 Incubate the cells for one more day
- 1.12 Harvest the dendritic cells on day 7 by collecting non adherent cells and loosely adherent cells. To release loosely adherent cells wash off the cells thoroughly by pipetting with culture medium I.
  Discard the adherent cells

# 2. Nucleofection™

## One Nucleofection™ Sample Contains

- 2.5×10<sup>4</sup> cells
- 0.4−0.8 μg plasmid DNA (in 1−2 μl H<sub>2</sub>O or TE) or 0.4 μg pmaxGFP<sup>™</sup> Vector or 30−300 nM siRNA (0.6−6 pmol/sample)
- 20 μl P3 Primary Cell 96-well Nucleofector™ Solution
- 2.1 Please make sure that the entire supplement is added to the Nucleofector™ Solution
- 2.2 Start Nucleofector™ 96-well Shuttle™ Software, verify device connection and upload experimental parameter file (for details see device and software manuals)
- 2.3 Select the appropriate 96-well Nucleofector™ Program **96-DN-107**
- 2.4 Prepare cell culture plates by filling appropriate number of wells with desired volume of culture medium I, e.g. 110 µI\* (see note at the end of this chapter) for one well of a 96-well plate and preincubate/equilibrate plates in a humidified 37°C/5 % CO<sub>2</sub> incubator
- 2.5 Pre-warm an aliquot of culture medium I to 37°C (80 µl per sample\*)
- 2.6 Prepare  $0.4-0.8 \mu g$  plasmid DNA or  $0.4 \mu g$  pmaxGFP<sup>M</sup> Vector or 30-300 nM siRNA (0.6-6 pmol/sample)
- 2.7 Count an aliquot of the cells and determine cell density
- 2.8 Centrifuge the required number of cells  $(2.5 \times 10^4 \text{ cells per sample})$  at  $300 \times g$  for 10 minutes at room temperature. Remove supernatant completely
- 2.9 Resuspend the cell pellet carefully in 20 µl room temperature 96well Nucleofector™ Solution per sample

## A: One or several substrates (DNAs or RNAs) in multiples

- Prepare mastermixes by dividing cell suspension according to number of substrates
- Add required amount of substrates to each aliquot (max. 2 µl per sample)
- Transfer 20 µl of mastermixes into the wells of the 96-well Nucleocuvette™ Modules

## B: Multiple substrates (e.g. Library Transfection)

- $-\,$  Pipette 20  $\mu I$  of cell suspension into each well of a sterile U- or V-bottom 96-well microtiter plate
- Add 2 µl substrates (maximum) to each well
- Transfer 20 µl of cells with substrates into the wells of the 96-well Nucleocuvette™ Modules

#### Note

It is advisable to pre-dispense each cell suspension into a sterile round-bottom 96-well plate or to pipet from a pipetting reservoir for multi-channel pipettes. Use a multi-channel or single-channel pipette with suitable pipette tips. As leaving cells in 96-well Nucleofector™ Solution for extended periods of time may lead to reduced transfection efficiency and viability it is important to work as quickly as possible. Avoid air bubbles while pipetting.

- 2.10 Gently tap the Nucleocuvette™ Plate to make sure the sample covers the bottom of the well
- 2.11 Place 96-well Nucleocuvette™ Plate with closed lid into the retainer of the 96-well Shuttle. Well "A1" must be in upper left position
- 2.12 Start 96-well Nucleofection™ Process by either pressing "Upload and start" in the 96-well Shuttle™ Software or pressing "Upload" in the 96-well Shuttle™ Software and then the "Start" button at the 96-well Shuttle™ (for both options please refer to the respective Manual)
- 2.13 After run completion, open retainer and carefully remove the 96-well Nucleocuvette™ Plate from the retainer
- 2.14 Resuspend cells with 80  $\mu$ l\* (recommendation for 96-well plates) or desired volume of pre-warmed culture medium I (maximum cuvette volume 200  $\mu$ l). Mix cells by gently pipetting up and down two to three times
- 2.15 Plate desired amount of cells in culture system of your choice. Recommendation for 96-well plates: Transfer 90  $\mu$ l of resuspended cells to 110  $\mu$ l pre-warmed culture medium I prepared in 96-well culture plates\*

## \* Note

The indicated cell numbers and volumes have been found to produce optimal 96-well Nucleofection™ Results in most cases. However, depending on your specific needs you may wish to test an extended range of cell numbers. Cell numbers and volumes can be adapted such that fewer cells are transferred or duplicate plates can be seeded.

# 3. Post Nucleofection™

3.1 Incubate the cells in a humidified  $37^{\circ}$ C/5 % CO<sub>2</sub> incubator until analysis. Gene expression or down regulation, respectively, is often detectable after only 4–8 hours

# Additional Information

# Up-To-Date List of all Nucleofector™ References

www.lonza.com/nucleofection-citations

# Technical Assistance and Scientific Support

USA/Canada

Tel 800 521 0390 (toll-free) Fax 301 845 8338 scientific.support@lonza.com

Europe and Rest of World

Tel + 49 221 99199 400 Fax + 49 221 99199 499 scientific.support.eu@lonza.com

# Reference

1. Inaba K. et al, (1992) J. Exp. Med. 176: 1693-1702

# www.lonza.com

Lonza Cologne GmbH – 50829 Cologne, Germany

Please note that the Amaxa" Nucleofector" Technology is not intended to be used for diagnostic purposes or for testing or treatment in humans. The Nucleofector" Technology, comprising Nucleofection" Process, Nucleofector" Device, Nucleofector" Solutions, Nucleofector" 96-well Shuttle" System and 96-well Nucleocuvette" plates and modules is covered by patent and/or patent-pending rights owned by Lonza Cologne GmbH. Amaxa, Nucleofector, Nucleofection, 96-well Shuttle, Nucleocuvette and maxGFP are either registered trademarks or trademarks of the Lonza Cologne GmbH in Germany and/or U.S. and/or other countries. FACSCalibur is a trademark of Becton Dickinson. TallTips are a registered trademark of Matrix Technologies Corporation. Other product and company names mentioned herein are the trademarks of their respective owners.

This kit contains a proprietary nucleic acid coding for a proprietary copepod fluorescent protein intended to be used as a positive control with this Lonza product only. Any use of the proprietary nucleic acid or protein other than as a positive control with this Lonza product is strictly prohibited. USE IN ANY OTHER APPLICATION REQUIRES A LICENSE FROM EVROGEN. To obtain such a license, please contact Evrogen at license@evrogen.com. The CMV promoter is covered under U.S. Patents 5,168,062 and 5,385,839 and its use is permitted for research purposes only. Any other use of the CMV promoter requires a license from the University of lowa Research Foundation, 214 Technology Innovation Center, lowa City, IA 52242. The use of this product in conjunction with materials or methods of third parties may require a license by a third party. User shall be fully responsible for determining whether and from which third party it requires such license and for the obtainment of such license. No statement is intended or should be construed as a recommendation to infringe any existing patent.

© Copyright 2009, Lonza Cologne GmbH. All rights reserved — D4SP-3006 2011-01